Mankind Pharma Limited today announced that it has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country.
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. The acquisition builds on Mankind Pharma’s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas.
Chronic therapies now account for a rising share of the company’s overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions.
Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, said:
This acquisition is aligned with our strategic focus on strengthening our presence in chronic therapies and specialty therapies. Going forward, we see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area. Leveraging our large field force and nationwide distribution network, we are well-positioned to build the brand and support physicians in delivering better outcomes for patients across India.”
Mankind Pharma will leverage its nationwide distribution network and large field force to support wider access to Rivotril across healthcare institutions and prescribers in India.
